The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of the Sleeve Gastrectomy Technique With a Nissen Fundoplication Added to the Conventional Sleeve Gastrectomy Technique in Morbidly Obese Patients (NSLEEVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04626232
Recruitment Status : Terminated (no inclusions)
First Posted : November 12, 2020
Last Update Posted : May 3, 2024
Sponsor:
Information provided by (Responsible Party):
University Hospital, Montpellier

Tracking Information
First Submitted Date  ICMJE October 8, 2020
First Posted Date  ICMJE November 12, 2020
Last Update Posted Date May 3, 2024
Actual Study Start Date  ICMJE September 12, 2022
Actual Primary Completion Date November 30, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 10, 2020)
  • Presence of gastroesophageal reflux disease [ Time Frame: 12 months ]
    Gastroscopy is a standard endoscopic examination that examines the lining of the oesophagus and stomach. It can detect Helicobacter pylori and highlight the presence of:
    • Gastro-Oesophageal Reflux Disease
    • Gastritis
    • Esophagitis
    • Barrett's oesophagus
    • Hiatal hernia
    • Gastric tumor
    • Bile reflux
    • Incompetent cardia
  • Consumption of Proton Pump Inhibitor [ Time Frame: 12 months ]
    The consumption of PPI, revealing the presence of GERD symptoms, will be recorded at each visit thanks a diary card.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: November 10, 2020)
  • type of fistula Month 1 [ Time Frame: Month 1 ]
    The diagnosis is confirmed by conducting a CT with contrast medium opacification. 4 stages are defined I, II, III and IV. TDM will be realized only in case of suspicion of fistulas (fever, pain in the left shoulder, vomiting). The type, the severity and the time between the date of occurrence of fistula and the date of the surgery will be recorded at each visit.
  • severity of fistula Month 1 [ Time Frame: Month 1 ]
    The severity of fistula is classified depending on the classification of Montpellier 2013 (Nedelcu)
  • type of fistula Month 6 [ Time Frame: Month 6 ]
    The diagnosis is confirmed by conducting a CT with contrast medium opacification. 4 stages are defined I, II, III and IV. TDM will be realized only in case of suspicion of fistulas (fever, pain in the left shoulder, vomiting). The type, the severity and the time between the date of occurrence of fistula and the date of the surgery will be recorded at each visit.
  • severity of fistula Month 6 [ Time Frame: Month 6 ]
    The severity of fistula is classified depending on the classification of Montpellier 2013 (Nedelcu)
  • type of fistula Month 12 [ Time Frame: Month 12 ]
    The diagnosis is confirmed by conducting a CT with contrast medium opacification. 4 stages are defined I, II, III and IV. TDM will be realized only in case of suspicion of fistulas (fever, pain in the left shoulder, vomiting). The type, the severity and the time between the date of occurrence of fistula and the date of the surgery will be recorded at each visit.
  • severity of fistula Month 12 [ Time Frame: Month 12 ]
    The severity of fistula is classified depending on the classification of Montpellier 2013 (Nedelcu)
  • Postoperative morbidity Month 1 [ Time Frame: Month 1 ]
    Assessed by the type of postoperative complication
  • Postoperative morbidity Month 6 [ Time Frame: Month 6 ]
    Assessed by the frequency of each type of postoperative complication
  • Postoperative morbidity Month 12 [ Time Frame: Month 12 ]
    Assessed by the severity of each type of postoperative complication
  • Weight loss Month 1 [ Time Frame: Month 1 ]
    The evolution of the weight of the patients will be assessed by measuring their weight in kilograms on the same scale at each visit in the digestive surgery service. The height (in meter) will be assessed at baseline in the digestive surgery service. The BMI will be calculated at each visit.
  • Weight loss Month 6 [ Time Frame: Month 6 ]
    The evolution of the weight of the patients will be assessed by measuring their weight in kilograms on the same scale at each visit in the digestive surgery service. The height (in meter) will be assessed at baseline in the digestive surgery service. The BMI will be calculated at each visit.
  • Weight loss Month 12 [ Time Frame: Month 12 ]
    The evolution of the weight of the patients will be assessed by measuring their weight in kilograms on the same scale at each visit in the digestive surgery service. The height (in meter) will be assessed at baseline in the digestive surgery service. The BMI will be calculated at each visit.
  • mortality Month 1 [ Time Frame: Month 1 ]
    number of death
  • mortality Month 6 [ Time Frame: Month 6 ]
    number of death
  • mortality Month 12 [ Time Frame: Month 12 ]
    number of death
  • Quality of Life Month 1 : SF 12 [ Time Frame: Month 1 ]
    Quality of life will be assessed by the self-questionnaire SF12
  • Quality of Life Month 6 : SF 12 [ Time Frame: Month 6 ]
    Quality of life will be assessed by the self-questionnaire SF12
  • Quality of Life Month 12 : SF 12 [ Time Frame: Month 12 ]
    Quality of life will be assessed by the self-questionnaire SF12
  • Serious adverse event Month 1 [ Time Frame: Month 1 ]
    number and type of adverse events
  • safety Month 6: number and type of adverse events [ Time Frame: Month 6 ]
    number and type of adverse events
  • safety Month 12: number and type of adverse events [ Time Frame: Month 12 ]
    number and type of adverse events
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Comparison of the Sleeve Gastrectomy Technique With a Nissen Fundoplication Added to the Conventional Sleeve Gastrectomy Technique in Morbidly Obese Patients
Official Title  ICMJE Monocentric Prospective Randomized Controlled Study Comparing the Sleeve Gastrectomy Technique With a Nissen Fundoplication Added to the Conventional Sleeve Gastrectomy Technique (N-Sleeve) in Morbidly Obese Patients
Brief Summary The purpose of this study is to evaluate the impact of the procedure (sleeve gastrectomy technique with a Nissen fundoplication (N-Sleeve) vs conventional sleeve gastrectomy technique
Detailed Description

Bariatric surgery is recognized as the only effective therapeutic weapon for morbidly obese patients. Gastro-Oesophageal Reflux Disease is very common (30-45% of cases) with serious consequences on the oesophageal mucosa. It could be an exacerbation of preoperative GERD symptoms or a "de novo" postoperative GERD. Medical treatment is usually effective but reoperation may be required to treat refractory GERD.GERD can lead to serious consequences on the oesophageal mucosa (esophagitis, Barrett's oesophagus, cancer). The conventional surgical treatment of GERD is fundoplication, which can be partial or total. The gastric fundus is wrapped around the oesophagus to strengthen the tone of the oesophageal sphincter. We hypothesize that the creation of a total anti-reflux fundoplication before performing LSG (Nissen + Sleeve = N-sleeve) could significantly reduce the postoperative GERD complication as compared with the standard LSG.

To evaluate the impact of the procedure N-Sleeve vs conventional sleeve gastrectomy technique on the rate of patient with GERD at 1, 6 and 12 months postoperatively. To evaluate the impact of the procedure (sleeve gastrectomy technique with a Nissen fundoplication (N-Sleeve) vs conventional sleeve gastrectomy technique during all the follow-up on the gastric fistula on the staple line, on the postoperative morbidity and mortality , on the evolution of weight loss, the excess weight loss, the BMI and the excess BMI loss during the follow-up. Evaluate the impact of these procedures on the quality of life of patients at baseline and 1, 6 and 12 months postoperatively. Evaluate the safety during all the follow-up.

•Methods: Monocentric, randomized, single-blind controlled trial, with 2 parallel arms. 144 patients. The target population is all adult patients with severe or morbid obesity, who underwent multidisciplinary care and having the criteria of 2009 HAS recommendations for bariatric surgery.

Presence of gastro-oesophageal reflux will be assessed by a composite criteria: consumption of Proton Pump Inhibitor and gastroscopy at baseline and 12-month.

The N-SLEEVE technique consists of creating a gastric total fundoplication before to perform the removal of 2/3 of the stomach.

This study may really lead to a change in terms of choice of first intention bariatric procedures.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Condition  ICMJE
  • Severe Obesity
  • GERD
  • Bariatric Surgery Candidate
  • Morbid Obesity
Intervention  ICMJE
  • Procedure: N-SLEEVE technique
    The N-SLEEVE technique (figure 2) consists of creating a gastric total fundoplication (Nissen technique) before to perform the removal of 2/3 of the stomach (SLEEVE technique).
  • Procedure: SLEEVE
    SLEEVE Technique : Removal of 2/3 of the stomach
Study Arms  ICMJE
  • Experimental: N SLEEVE
    Monocentric, randomized, single-blind controlled trial, with 2 parallel arms (experimental technique versus surgical reference technique).
    Intervention: Procedure: N-SLEEVE technique
  • SLEEVE
    The conventional sleeve gastrectomy technique consists of reducing the gastric capacity by removing 2/3 of the stomach by a vertical transection.
    Intervention: Procedure: SLEEVE
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: May 2, 2024)
2
Original Estimated Enrollment  ICMJE
 (submitted: November 10, 2020)
144
Actual Study Completion Date  ICMJE November 30, 2022
Actual Primary Completion Date November 30, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Signed informed consent form
  • Subjects must be able to attend all scheduled visits and to comply with all trial procedures
  • Subjects must be covered by public health insurance
  • Contraception efficacy
  • Subjects eligible for sleeve gastrectomy after multidisciplinary evaluation according to HAS 2009 criteria: BMI ≥ 40 kg / m² with failure of the dietary treatment for at least 1 year, or a BMI ≥ 35kg / m² with at least one co-morbidity that could be improved after surgery (hypertension, obstructive sleep apnea hypopnea syndrome (OSAHS) and other severe respiratory disorders, severe metabolic disorders (especially type 2 diabetes), debilitating musculoskeletal diseases, non-alcoholic steato-hepatitis (NASH))

Exclusion Criteria:

  • Subject unable to read or/and write
  • Planned longer stay outside the region that prevents compliance with the visit plan
  • Current pregnancy
  • Previous bariatric surgery (ring, vertical banded gastroplasty, sleeve gastrectomy or Gastric Bypass).
  • BMI > 50 kg / m² for women and > 45kg / m² for men (dissecting the hiatus region can be a technical challenge in these cases).
  • Barrett oesophagus and esophagitis stage III and IV.
  • Funditis
  • Long-term NSAIDs and/or corticosteroid therapy
  • No affiliation at the French social security scheme.
  • Major protected by law.
  • Deprivation of liberty by judicial or administrative decision.
  • Participation to another clinical research program.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE France
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04626232
Other Study ID Numbers  ICMJE RECHMPL20-0013 PROM 7925
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party University Hospital, Montpellier
Original Responsible Party Same as current
Current Study Sponsor  ICMJE University Hospital, Montpellier
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account University Hospital, Montpellier
Verification Date May 2024

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP